Pregnancy entails a hormonal revolution that has repercussions on the entire body and some of its symptoms can be especially unpleasant, such as the nausea and vomiting that most pregnant women experience and which deteriorate their quality of life. Now, the pharmaceutical company Italfarmaco has launched the CARIBENE study with the aim of alleviating these discomforts.
During the first months of pregnancy, nausea affects 70-85% of pregnant women, and 50% of pregnant women experience vomiting. They usually occur early in the day and in most cases disappear after week 20 of pregnancy, as explained in the Pregnancy Care Guide, published by the University Hospital of Ceuta.
Although they are associated with a lower risk of suffering an abortion, according to experts from the Mayo Clinic, they have a significant impact on the quality of life of pregnant women, especially those who experience more serious symptoms that interfere with their work activity. performing domestic tasks, caring for children, couple and social relationships, and the emotional and psychological well-being of women.
Assess the well-being of the pregnant woman with nausea and vomiting
Italfarmaco Group, a leader in the research and development of medicines and committed since its inception to women’s health and the quality of life of patients – which has become one of the main objectives that health professionals and development must pursue of medicines – has launched the CARIBENE study.
“Nausea and vomiting during pregnancy are underestimated and undertreated. CARIBENE will allow us to demonstrate the effectiveness of treatment with doxylamine/pyridoxine when a regimen adapted to the patient is used.”
CARIBENE is a multicenter clinical trial carried out in Spain, which includes the participation of approximately 80 pregnant women who suffer from nausea and vomiting. This study aims to evaluate how treatment with a fixed combination of doxylamine/pyridoxine 10/10mg (Cariban®) – the only combination approved in Spain for the treatment of nausea and vomiting during pregnancy from which hundreds of thousands of women have benefited since years ago – can improve the quality of life of pregnant women, using a regimen adapted to the appearance and intensity of symptoms.
CARIBENE is a pioneering study at the national level and innovative at the international level, since for the first time it focuses on evaluating the well-being of pregnant women with nausea and vomiting during pregnancy with this treatment.
Dr. Juan Luis Delgado, head of the obstetrics section at the Virgen de la Arrixaca Clinical Hospital in Murcia and coordinator of the study, states that “even today, health professionals and patients often continue to incorrectly address this clinical condition: nausea. and vomiting of pregnancy are underestimated and undertreated, using treatments for symptomatic relief, and on demand. CARIBENE will allow us to demonstrate the effectiveness of treatment with doxylamine/pyridoxine when a regimen adapted to the patient is used and on a continuous basis. And it will allow us to know what aspects of our pregnant women’s well-being we can improve from the consultation with the help of pharmacological treatment, beyond the symptoms themselves.”
